Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mulTi-Arm Therapeutic study in pre-ICU patients admitted with Covid-19 – Experimental drugs and mechanisms
2020-002229-27Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2020
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of dapagliflozin, ambrisentan and EDP1815 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Time to progression to organ failure or death. Status: unknown.
02
Drugs
dapagliflozinambrisentanEDP1815
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002229-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002229-27.